For a more complete overview of how GLP-1 side effects can show up, our guide on GLP-1 side effects is a useful companion
however, these relationships were small in magnitude (r = 0.097 and 0.113, respectively)
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
doi: 10.1111/head.12113 222
Source list Barrea, L., Annunziata, G., Verde, L., et al
Molecular docking simulations showed TXNDC5 K150 at the contact surface between USP2 and TXNDC5 (Fig
